This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
GeparSixto was a randomized phase 2/3 trial evaluating the addition of carboplatin to neoadjuvant therapy for patients with early breast cancer.
| Feature | GeparSixto |
|---|---|
| Phase | 2/3 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | GBG Forschungs GmbH |
| Interventions | Carboplatin and background treatment |
2. Clinical Question
Population
Patients with conditions including triple-negative and HER2-positive early breast cancer as recorded in the registry.
Intervention
Addition of carboplatin to neoadjuvant therapy.
Comparator
Background treatment without the additional carboplatin intervention.
Primary question
Does adding carboplatin influence pathological complete response of breast and lymph nodes?
3. Trial Design
595 patients
2 arms
Therapy
Assessment
Endpoint
4. Endpoints
| Endpoint | Time Frame | Description |
|---|---|---|
| Pathological complete response of breast and lymph nodes (ypT0 ypN0; primary endpoint) | 24 weeks (time window -3 weeks) | Pathological response assessed considering all removed breast and lymphatic tissues from surgeries. No microscopic evidence of residual viable tumor cells in breast and axilla meets the endpoint. |
5. Planned Analysis
The registry identifies pathological complete response of breast and lymph nodes as the primary endpoint. For a binary pathological response endpoint, the statistical analysis would typically compare the proportion of patients achieving complete response between randomized groups using an appropriate two-group comparison method.
6. Statistical Methodology
The design uses random allocation in a parallel-group treatment comparison. Randomization provides the framework for comparing treatment groups while reducing the influence of measured and unmeasured baseline differences.
Binary endpoint analysis
Pathological complete response is a categorical outcome: each patient either meets the prespecified pathological definition or does not. Analyses of such endpoints commonly focus on differences in response proportions, confidence intervals, and hypothesis testing.
Response rate = patients meeting the pathological complete response definition ÷ analyzed patients
7. Statistical Methods Explained
Why is pathological complete response suitable as an endpoint?
A pathological complete response endpoint directly measures absence of residual viable tumor cells in specified surgical specimens after neoadjuvant therapy.
Why does randomization matter?
Randomization creates treatment groups intended to be comparable at baseline, supporting causal interpretation of differences between groups.
Why are proportions used for this endpoint?
The outcome is whether a prespecified pathological event occurred, making it naturally summarized as a proportion of patients.
What does a confidence interval add?
A confidence interval describes uncertainty around an estimated treatment difference or effect measure rather than simply indicating whether a threshold was crossed.
8. Limitations
- The ClinicalTrials.gov record does not report posted statistical analyses or endpoint results.
- Detailed baseline characteristics are not reported in the registry information summarized here.
- Long-term outcomes and subgroup analyses are not reported in the registry record.
- The registry does not report details of multiplicity adjustment, interim analyses, missing-data handling, or imputation methods.
9. Why This Trial Matters Statistically
| Concept | How it appears in GeparSixto |
|---|---|
| Randomization | Randomized parallel-group treatment comparison |
| Binary endpoint | Pathological complete response |
| Neoadjuvant assessment | Outcome measured after systemic therapy and surgery |
| Clinical trial methodology | Phase 2/3 randomized evaluation |